J&J’s OROS Hydromorphone Requires Additional Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Following meetings with FDA, the company will modify the development program for the chronic pain agent.
You may also be interested in...
Neuromed Deal With Alza Will Accelerate Commercialization Strategy
Neuromed will develop a sales force to launch OROS hydromorphone in the U.S. in 2009 under a collaboration with the J&J subsidiary.
Neuromed Deal With Alza Will Accelerate Commercialization Strategy
Neuromed will develop a sales force to launch OROS hydromorphone in the U.S. in 2009 under a collaboration with the J&J subsidiary.
OROS Hydromorphone Development Unaffected By Palladone Withdrawal, J&J Says
Johnson & Johnson says that the withdrawal of Purdue Pharma's Palladone (hydromorphone extended release) will not affect development of its OROS hydromorphone opioid analgesic